Articles tagged with Kidney
Researchers have successfully bioprinted miniature human kidneys in a lab using cutting-edge technology. The study validates the use of 3D bioprinted human mini-kidneys for screening drug toxicity, paving the way for new treatments and potentially lab-grown transplants.
Acute kidney injury (AKI) is common among hospitalized US veterans with COVID-19, with nearly half not fully recovering their kidney function. The burden of death from AKI is disproportionately borne by Black veterans.
Patients with chronic kidney disease can proactively manage their health by receiving tailored guidance on diet and lifestyle. Effective communication with doctors and strong family support are also crucial in empowering patients to take a more active role in their care. This study highlights the importance of clearer information, bett...
A new study published in the American Journal of Transplantation shows that simultaneous robotic-assisted kidney transplant and weight loss surgery is safe for obese patients. The procedure resulted in a significant reduction in surgical complications and improved cardiac function, with all patients experiencing a substantial weight loss.
A new equation for estimating glomerular filtration rate (GFR) shows improved accuracy and precision compared to commonly used equations. The European Kidney Function Consortium's (EKFC) equation addresses limitations of existing methods and is suitable for a wide age range.
A unique biomarker combination predicts Acute Kidney Injury (AKI) in critically ill children, enabling early identification and potential pre-emptive therapy. The study found that a combination of clinical scores and urinary markers can accurately predict severe AKI in PICU admissions.
Combination therapy of verinurad and febuxostat significantly lowers urinary albumin excretion and uric acid levels in people with chronic kidney disease and type 2 diabetes. The treatment is generally well-tolerated, with minimal adverse events reported.
A six-month mass media campaign, Living Donation Storytelling Project, aims to capture 500 living donor kidney transplant (LDKT) stories, educating medical providers and patients about innovative resources. The project uses digital storytelling to supplement traditional education practices, allowing real people to share their experiences.
Social determinants like discrimination, depression, and mistrust predict patient-reported quality of life in kidney transplant patients. Lower medical mistrust leads to greater patient satisfaction with clinical services.
A study analyzing 60,229 patients found that Black patients are less likely to be referred for transplantation and more likely to receive a transplant after referral, but ultimately less likely to receive a transplant overall. Racial disparities in the transplant process emerge at listing stage and persist through organ allocation
A new machine learning-based model predicts atrial fibrillation risk in chronic kidney disease patients, providing a potential tool for enhanced cardiovascular care and clinical trial selection.
A new AI-based algorithm can predict which hospitalized patients with COVID-19 are at risk of developing acute kidney injury (AKI) requiring dialysis. The model achieved high accuracy using data from over 3,000 patients and key features such as creatinine and potassium levels, age, and vital signs.
A new AI-based tool can help clinicians predict which hospitalized patients are at high risk of developing acute kidney injury, allowing for earlier treatment and potentially better outcomes. The Dascena algorithm outperformed the standard method in predicting AKI 72 hours prior to onset.
A research team discovered molecular processes in kidney cells that attract and feed COVID-19, making them a target for potential therapies. The study identified networks of molecules that result in higher levels of ACE2, a protein on the surface of kidney cells that aids in virus entry and activation.
A clinical trial published in the New England Journal of Medicine shows that finerenone significantly slows the progression of diabetic kidney disease by 18% compared to a placebo. The study also found a reduction in cardiovascular event rates, offering new treatment options for patients with chronic kidney disease and type 2 diabetes.
Recent clinical trials have shown promising results for finerenone, which slows diabetic kidney disease progression and reduces cardiovascular events when added to standard care. Empagliflozin also demonstrated benefits in patients with heart failure and chronic kidney disease. These findings suggest new treatment options for patients ...
A study found that online peer mentoring for individuals with chronic kidney disease (CKD) improves patient activation, which is positively correlated with various aspects of quality of life. Improved patient activation correlates with improvements in physical symptoms and burdens of kidney disease but not mental aspects.
A new study examines the risk of acute kidney injury among Black individuals with sickle cell trait and disease, finding a higher risk for acute kidney injury and faster loss of kidney function. The study adds important information to sparse data on the risk of acute kidney injury in those carrying the sickle cell gene.
A new study found that Blacks and Hispanics experience higher rates of kidney failure compared to whites, driven by faster declines in kidney function after chronic kidney disease onset. This disparity can be addressed by slowing the progression of kidney disease in these populations.
A new study found that similar molecular processes are activated in diabetic kidney disease and COVID-19 patients, making them more susceptible to infection. The research suggests that diabetes primes kidney cells, which can lead to a severe immune response and kidney damage when combined with COVID-19.
ERA-EDTA has launched a series of e-seminars to apply recent trial findings to patient care. The e-seminars focus on topics like SGLT2 inhibitors and COVID-19, aiming to provide nephrology experts with insights into the benefits and risks of new treatments.
Glomerular diseases significantly increase the risk of cardiovascular disease, affecting blood cleaning units in the kidneys. A study analyzing 2000-2012 data found a 2.5-times higher risk compared to the general population.
Researchers analyzed 1,347 nephrectomy specimens to understand kidney histopathological findings. They found that more scarring in glomerulus, tubules/interstitium, and vessels is associated with worse kidney function.
Higher serum creatinine-to-cystatin C ratios are associated with lower mortality rates in patients initiating continuous renal replacement therapy for acute kidney injury. This simple tool may improve mortality risk assessment in critically ill patients developing AKI.
The MDI Biological Laboratory has received a grant to develop artificial kidney tissue to replace human kidney tissue lost due to disease or injury. The project aims to create a three-dimensional mini-organ called an organoid that can be transplanted into a host and potentially scaled to create an artificial human kidney.
Researchers found that patients with chronic kidney disease (CKD) or acute kidney injury (AKI) due to COVID-19 had significantly higher mortality rates in intensive care, with mortality rates ranging from 21% for those without kidney injury to 86% for patients with kidney transplants. The study highlights the need for calibration of IC...
Researchers found that using the race multiplier correction factor for Black patients with chronic kidney disease can lead to delayed referrals and critical conversations about dialysis. Removing this factor could reclassify up to one-third of Black patients to a more severe stage of CKD.
Dr. Adebiyi's research investigates newborn kidney functions and their alterations in acute and long-term disease, with a focus on growth-restricted infants. The new $3 million grant will explore the cellular mechanisms underlying progressive kidney insufficiency in these babies.
Researchers identify key risk factors for acute kidney injury (AKI) in patients with intracerebral hemorrhage (ICH), including higher baseline serum creatinine levels and higher doses of nicardipine, which increase the risk of AKI and death within three months
A Mayo Clinic study found that patients with large polycystic kidneys can have their diseased kidneys removed laparoscopically at the same time as a kidney transplant, without compromising kidney function. The dual surgery approach has been shown to be a safe and viable option for these patients.
A team of researchers from Osaka University has identified the crucial role of lipids, lysosomes, and autophagy in preventing kidney injury. By understanding how calcium, lipids, and lysosomal degradation interact, scientists can develop new treatments for kidney damage caused by crystal-induced injuries.
A new study from Boston University School of Medicine found that an alpha adrenoceptor blocker may treat salt-sensitive hypertension by reducing a kidney mechanism that reabsorbs salt. This approach shows promise in treating high blood pressure associated with dietary salt intake.
Researchers at UNSW Science discovered a new molecular pathway that controls Shiga toxin production in E. coli, which could lead to the development of drugs suppressing toxin production during infections. The study's findings provide a potential breakthrough for treating severe E. coli infections.
A new observational study reveals that COVID-19 patients with elevated suPAR levels are more likely to develop kidney injury and require dialysis. High suPAR levels were found in nearly three times the number of severe COVID-19 patients compared to healthy individuals.
Researchers identified process and outcome indicators to monitor transplant center performance in evaluating potential living kidney donors. The study aims to improve efficiency and increase living kidney donations.
Observational study finds COVID-19 patients with high suPAR levels are at increased risk for acute kidney injury and death. Elevated suPAR levels were found in over a third of patients hospitalized with COVID-19, leading to a 20-fold increase in dialysis needs.
Researchers found that diabetes increases autophagy initially, but then decreases it due to the activation of tumor suppressor p53 and microRNA miR-214, leading to hypertrophy, scarring, and inflammation in the kidneys. This discovery offers a potential target for preventing or slowing kidney failure.
A recent study found that COVID-19 patients with kidney damage are at a significantly higher risk of in-hospital mortality. The study analyzed data from 1,392 patients and found that kidney damage was associated with a 5-times higher odds of dying while in the hospital.
Researchers developed a tailored education system called 'Your Path to Transplant' that increases patient knowledge and readiness to pursue kidney transplant. The program, tested on over 800 patients, showed significant improvements in transplant preparedness and living donor transplant rates.
Researchers discover cancer drug improves kidney dysfunction in mouse model of Lowe syndrome and Dent disease 2, offering hope for first disease-modifying treatment. The study suggests that alpelisib could also help alleviate neurological symptoms.
Researchers found that prophylactic treatment with direct-acting antivirals prevented chronic hepatitis C virus infection in patients receiving kidneys from HCV-positive deceased donors. The approach has potential to shorten waiting times on the organ waitlist.
Researchers describe ways to achieve optimal patient advocacy for kidney recipients and donors during the COVID-19 pandemic. Key areas include informing patients fully in their care decision process and honoring patient priorities in all care innovations and policies.
A systematic review of over 100 studies found that a more vegetable-rich diet, higher potassium intake, and reduced salt consumption can lower the risk of chronic kidney disease. Adhering to these recommendations could reduce the risk by 14-22%.
Researchers from Massachusetts General Hospital have successfully treated hepatitis C-infected kidneys in transplant patients using glecaprevir and pibrentasvir. The study shows that early antiviral intervention can cure the virus without serious side effects, paving the way for a significant increase in organ availability.
Two randomized controlled studies demonstrate that SGLT2 inhibitors can slow CKD progression across all patient groups, not just those with diabetes. The DAPA-CKD trial found a significant reduction in kidney function decline and end-stage disease with dapagliflozin treatment.
A new study has found that measuring the ratio of two proteins in deceased donor urine can identify kidneys with a higher probability for successful transplantation and long-term survival. The researchers believe this biomarker could help reduce the number of discarded kidneys and increase the organ donation pool.
A new analysis by Children's National Hospital researchers found that reducing proteinuria in patients with FSGS significantly slows declines in kidney function and extends time before kidneys fail. The study showed that even modest reductions in proteinuria have a positive impact on kidney health.
Research highlights the link between Alport syndrome genotype and treatment effectiveness with ACE inhibitors and RAS blockers, showing varied responses to treatment depending on mutation type and age of progression to end-stage kidney disease.
A new online tool developed by Hennepin Healthcare Research Institute and the University of Minnesota helps transplant candidates find matching programs based on their donor type and medical profile. The website uses data from the Scientific Registry of Transplant Recipients (SRTR) to provide personalized decision support.
A new NIH study demonstrates that kidney transplantation between people with HIV can be done safely and effectively. The study found excellent graft survival rates, comparable to those of recipients receiving kidneys from HIV-negative donors, without significant differences in infection or adverse events rates.
Researchers at UConn Health have developed a non-invasive biomarker panel for diagnosing and monitoring infant urinary tract obstruction. The panel of five proteins can detect UPJO in infants and toddlers, reducing the need for expensive and invasive tests.
A new Northwestern University study in mice found ACE inhibitors and angiotensin receptor blockers do not increase COVID-19 severity or fatality risk. The research dispels concerns about these widely used drugs in patients with hypertension and cardiovascular disease.
Researchers analyzed patient preferences for waiting time, post-graft life expectancy, infection risk, and neoplastic risk. Including patient preferences in the algorithm improves patient satisfaction and expected graft survival rates.
A study of 9,029 adults found that cystatin C-based kidney function was associated with lower odds of frailty, falls, and cardiovascular disease events. The difference between cystatin C- and creatinine-based kidney function could be used to predict adverse outcomes in older adults.
A large international study found that starting dialysis early in critically ill patients with acute kidney injury did not reduce mortality after three months. The accelerated renal-replacement therapy strategy did not show significant difference in survival between the two treatment approaches.
A major multinational trial found that fast-tracking dialysis for critically ill patients with severe acute kidney injury did not improve outcomes. The study included over 3,000 patients in 168 hospitals across 15 countries and suggested a more conservative approach to treatment may be warranted.
Researchers at Newcastle University have discovered a new technique that can improve the function of 'marginal' kidneys, increasing urine production and improving blood flow to damaged cells. The treatment uses a type of stem cell called MultiStem to deliver anti-inflammatory molecules.
Researchers used a novel imaging agent to visualize inter-organ communication between the heart and kidneys via the immune system following acute myocardial infarction. The study found a systemic inflammatory response, suggesting a potential mechanism for disease progression and therapy response.
A new clinical trial from the University of Minnesota Medical School found that allopurinol did not slow kidney function in people with type 1 diabetes, despite reducing uric acid levels. The three-year study enrolled 530 participants and followed their glomerular filtration rate to assess kidney health.
A clinical trial found that reducing uric acid levels with the medication allopurinol did not slow the progression of kidney disease in people with type 1 diabetes. Despite a significant drop in uric acid levels, participants showed no improvement in their kidney function.